procarbazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
2272 671-16-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • procarbazine
  • ibenzmethyzine
  • procarbazine hydrochloride
  • procarbazine HCl
An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
  • Molecular weight: 221.30
  • Formula: C12H19N3O
  • CLOGP: -0.08
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 3
  • TPSA: 53.16
  • ALOGS: -2.99
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 g O

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 27.11 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
S (Water solubility) 100 mg/mL Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Bocci G, Oprea TI, Benet LZ
BA (Bioavailability) 100 %

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,AKT2,ALK,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,IKBKB,ITK,JAK2,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MET,MTOR,NTRK2,PDK2,PDK4,PIK3CB,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 46
kinase-selectivity-class AKT3,AXL,CDK4,EIF2AK3,GRK2,GRK3,PDK1,SIK2 8
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
July 22, 1969 FDA SIGMA TAU

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatitis B reactivation 318.38 33.64 67 4836 3907 90619637
Acute hepatic failure 183.13 33.64 62 4841 22499 90601045
Nausea 155.89 33.64 240 4663 1110076 89513468
Full blood count abnormal 130.10 33.64 55 4848 36542 90587002
Neutropenia 98.87 33.64 88 4815 224816 90398728
Thrombocytopenia 90.39 33.64 81 4822 208644 90414900
Hepatic cytolysis 88.80 33.64 40 4863 30876 90592668
Fatigue 74.47 33.64 180 4723 1153843 89469701
Disease progression 74.20 33.64 64 4839 156551 90466993
Basal ganglion degeneration 64.41 33.64 12 4891 370 90623174
Necrotising gastritis 60.23 33.64 9 4894 67 90623477
Tissue infiltration 60.14 33.64 13 4890 857 90622687
Platelet count decreased 58.90 33.64 53 4850 136916 90486628
Anaesthesia 55.95 33.64 11 4892 453 90623091
Uterine enlargement 54.47 33.64 13 4890 1335 90622209
Febrile neutropenia 54.20 33.64 54 4849 158295 90465249
Maternal exposure before pregnancy 54.08 33.64 21 4882 11192 90612352
Myelodysplastic syndrome 53.59 33.64 25 4878 20878 90602666
Second primary malignancy 52.06 33.64 20 4883 10358 90613186
Hepatocellular injury 51.50 33.64 27 4876 28931 90594613
Psychogenic seizure 49.28 33.64 13 4890 2003 90621541
Inguinal hernia 48.76 33.64 13 4890 2085 90621459
Constipation 45.01 33.64 65 4838 280330 90343214
Neurological decompensation 42.18 33.64 13 4890 3488 90620056
Monoplegia 41.56 33.64 13 4890 3661 90619883
Dysaesthesia 40.86 33.64 14 4889 5241 90618303
Psychiatric decompensation 40.27 33.64 11 4892 1932 90621612
Hypochromic anaemia 39.07 33.64 11 4892 2160 90621384
Persecutory delusion 39.02 33.64 12 4891 3196 90620348
Cytomegalovirus myocarditis 38.75 33.64 6 4897 58 90623486
White blood cell count decreased 38.02 33.64 46 4857 167063 90456481
Hepatitis G 36.51 33.64 6 4897 87 90623457
Intervertebral disc disorder 36.51 33.64 13 4890 5447 90618097
Aplasia 36.44 33.64 12 4891 3979 90619565
Visceral leishmaniasis 35.47 33.64 8 4895 641 90622903
Splenomegaly 34.81 33.64 16 4887 12908 90610636
Malignant neoplasm progression 33.89 33.64 35 4868 106835 90516709
Meningoencephalitis herpetic 33.72 33.64 9 4894 1450 90622094

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia 307.64 29.05 112 5127 22144 42593952
Second primary malignancy 229.98 29.05 73 5166 9502 42606594
Nausea 209.62 29.05 249 4990 396550 42219546
Fatigue 158.83 29.05 228 5011 435413 42180683
Myelodysplastic syndrome 127.08 29.05 60 5179 22685 42593411
Malignant transformation 124.81 29.05 28 5211 950 42615146
Neutropenia 110.78 29.05 129 5110 199302 42416794
Blood stem cell transplant failure 96.91 29.05 20 5219 453 42615643
Myositis 76.24 29.05 37 5202 14829 42601267
Full blood count abnormal 66.62 29.05 43 5196 29833 42586263
Hepatocellular injury 60.10 29.05 37 5202 23641 42592455
Neoplasm progression 55.61 29.05 38 5201 28962 42587134
Disease progression 52.91 29.05 76 5163 143580 42472516
Transformation to acute myeloid leukaemia 51.05 29.05 14 5225 1091 42615005
Premature ageing 43.84 29.05 8 5231 92 42616004
Hepatic cancer 43.14 29.05 21 5218 8459 42607637
Malignant neoplasm progression 42.31 29.05 59 5180 108341 42507755
Angiodysplasia 40.91 29.05 11 5228 796 42615300
Hepatic cytolysis 37.39 29.05 29 5210 26815 42589281
Platelet count decreased 36.64 29.05 63 5176 138518 42477578
Heart disease congenital 34.60 29.05 11 5228 1431 42614665
Leukoencephalopathy 33.69 29.05 15 5224 4939 42611157
Neuropathy peripheral 33.29 29.05 51 5188 101802 42514294
Constipation 33.12 29.05 66 5173 162225 42453871
Herpes simplex encephalitis 33.12 29.05 8 5231 376 42615720
Congenital hepatobiliary anomaly 30.44 29.05 5 5234 29 42616067
Flagellate dermatitis 29.73 29.05 6 5233 121 42615975
Hair growth abnormal 29.58 29.05 9 5230 1013 42615083

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute myeloid leukaemia 333.34 28.28 118 7580 37992 110543609
Second primary malignancy 291.84 28.28 89 7609 17979 110563622
Neutropenia 197.33 28.28 181 7517 374439 110207162
Myelodysplastic syndrome 183.21 28.28 76 7622 37408 110544193
Hepatic cytolysis 131.67 28.28 68 7630 54985 110526616
Disease progression 130.32 28.28 119 7579 243915 110337686
Malignant transformation 122.70 28.28 27 7671 1498 110580103
Hepatocellular injury 122.40 28.28 63 7635 50579 110531022
Malignant neoplasm progression 96.77 28.28 87 7611 174480 110407121
Febrile neutropenia 87.73 28.28 109 7589 316658 110264943
Blood stem cell transplant failure 82.17 28.28 17 7681 701 110580900
Neoplasm progression 79.94 28.28 52 7646 64543 110517058
Thrombocytopenia 73.44 28.28 105 7593 348780 110232821
Myositis 73.11 28.28 38 7660 31078 110550523
Necrotising gastritis 64.22 28.28 10 7688 76 110581525
Basal ganglion degeneration 59.80 28.28 12 7686 424 110581177
Uterine enlargement 55.26 28.28 13 7685 972 110580629
Tissue infiltration 54.52 28.28 13 7685 1030 110580571
Anaesthesia 50.29 28.28 11 7687 593 110581008
Hepatitis B reactivation 49.88 28.28 19 7679 7465 110574136
Leukoencephalopathy 49.50 28.28 20 7678 9175 110572426
Febrile bone marrow aplasia 48.84 28.28 24 7674 17441 110564160
Premature ageing 47.77 28.28 8 7690 100 110581501
Paraparesis 47.04 28.28 16 7682 4550 110577051
Bone marrow failure 46.95 28.28 36 7662 57812 110523789
Hepatic cancer 45.77 28.28 20 7678 11136 110570465
Psychogenic seizure 43.98 28.28 13 7685 2351 110579250
Pancytopenia 42.44 28.28 62 7636 209551 110372050
Full blood count abnormal 41.42 28.28 33 7665 56019 110525582
Dysaesthesia 40.71 28.28 16 7682 6831 110574770
Off label use 40.46 28.28 208 7490 1499977 109081624
Angiodysplasia 40.33 28.28 11 7687 1491 110580110
Osteonecrosis 38.90 28.28 26 7672 33715 110547886
Product use in unapproved indication 37.96 28.28 91 7607 447286 110134315
Benign prostatic hyperplasia 36.44 28.28 20 7678 18214 110563387
Haematotoxicity 36.37 28.28 21 7677 21061 110560540
Transformation to acute myeloid leukaemia 35.58 28.28 10 7688 1513 110580088
Pneumocystis jirovecii pneumonia 35.57 28.28 27 7671 42708 110538893
Peripheral sensory neuropathy 35.29 28.28 19 7679 16661 110564940
Cytomegalovirus myocarditis 35.00 28.28 6 7692 87 110581514
Monoplegia 34.66 28.28 13 7685 4896 110576705
Neurological decompensation 33.74 28.28 14 7684 6869 110574732
Hepatitis G 33.68 28.28 6 7692 110 110581491
Intervertebral disc disorder 33.19 28.28 13 7685 5499 110576102
Septic shock 32.45 28.28 47 7651 157481 110424120
Therapy partial responder 32.14 28.28 24 7674 37037 110544564
Hypochromic anaemia 32.12 28.28 11 7687 3190 110578411
Acute kidney injury 32.01 28.28 107 7591 635323 109946278
Herpes simplex encephalitis 31.37 28.28 8 7690 837 110580764
Mucocutaneous leishmaniasis 29.75 28.28 7 7691 524 110581077
Klebsiella infection 29.47 28.28 18 7680 19991 110561610
Drug clearance decreased 29.41 28.28 11 7687 4111 110577490
Meningoencephalitis amoebic 29.22 28.28 6 7692 238 110581363
Inguinal hernia 28.96 28.28 13 7685 7712 110573889
Spindle cell sarcoma 28.75 28.28 6 7692 258 110581343
Acanthamoeba infection 28.63 28.28 7 7691 616 110580985

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01XB01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Methylhydrazines
FDA MoA N0000000236 Alkylating Activity
FDA EPC N0000175558 Alkylating Drug
MeSH PA D000970 Antineoplastic Agents
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hodgkin's disease indication 118599009
Astrocytoma, anaplastic off-label use 55353007 DOID:3078
Diffuse non-Hodgkin's lymphoma, large cell off-label use 109969005
Polycythemia vera off-label use 109992005
Mycosis fungoides off-label use 118618005
Glioblastoma multiforme of brain off-label use 276828006 DOID:3073
Malignant neoplasm of brain off-label use 428061005 DOID:1319
Mycosis contraindication 3218000 DOID:1564
Alcoholism contraindication 7200002
Viral disease contraindication 34014006 DOID:934
Acute nephropathy contraindication 58574008
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Leukopenia contraindication 84828003 DOID:615
Bacterial infectious disease contraindication 87628006
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Peripheral nerve disease contraindication 302226006
Bone marrow depression contraindication 307762000
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002
Protozoal Infection contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.29 acidic
pKa2 7.0 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
4019906 VUID
N0000147991 NUI
D00478 KEGG_DRUG
366-70-1 SECONDARY_CAS_RN
4017789 VANDF
4019906 VANDF
C0033223 UMLSCUI
CHEBI:71417 CHEBI
CHEMBL1321 ChEMBL_ID
DB01168 DRUGBANK_ID
CHEMBL1200410 ChEMBL_ID
D011344 MESH_DESCRIPTOR_UI
4915 PUBCHEM_CID
7278 IUPHAR_LIGAND_ID
2147 INN_ID
35S93Y190K UNII
66925 RXNORM
5360 MMSL
d00354 MMSL
002672 NDDF
004827 NDDF
10174003 SNOMEDCT_US
387474003 SNOMEDCT_US
81583003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Matulane HUMAN PRESCRIPTION DRUG LABEL 1 54482-054 CAPSULE 50 mg ORAL NDA 23 sections